Mesoblast Ltd

MESO

Company Profile

  • Business description

    Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

  • Contact

    55 Collins Street
    Level 38
    MelbourneVIC3000
    AUS

    T: +61 396396036

    E: [email protected]

    https://www.mesoblast.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    73

Stocks News & Analysis

stocks

Unconventional wisdom: Are dividends the answers?

As investors toil in complexity the obvious solution may be the right one.
stocks

Netflix: A business that’s nearly flawless

Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks

Trump’s US dollar assault is fuelling CBA’s rise

A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,930.4049.00-0.55%
CAC 407,818.2832.15-0.41%
DAX 4024,295.9355.110.23%
Dow JONES (US)44,693.91316.38-0.70%
FTSE 1009,138.3776.880.85%
HKSE25,534.92132.26-0.52%
NASDAQ21,057.9637.940.18%
Nikkei 22541,580.12246.22-0.59%
NZX 50 Index12,848.2643.130.34%
S&P 5006,363.354.440.07%
S&P/ASX 2008,660.6048.80-0.56%
SSE Composite Index3,603.282.45-0.07%

Market Movers